Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: Implications for multimodal therapy

International Journal of Urology

Volumn 20, Issue 6, 2013, Pages 572-579

  Capitanio, Umberto ^a   Abdollah, Firas ^a   Matloob, Rayan ^a   Salonia, Andrea ^a   Suardi, Nazareno ^a   Briganti, Alberto ^a   Carenzi, Cristina ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a   Bertini, Roberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Cancer specific survival; Cytoreductive surgery; Metastases; Nephrectomy; Renal cell carcinoma

Indexed keywords

HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADRENAL METASTASIS; AMERICAN SOCIETY OF ANESTHESIOLOGISTS SCORE; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CYTOREDUCTIVE SURGERY; DISTANT METASTASIS; GAMMA KNIFE RADIOSURGERY; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS RESECTION; NEPHRECTOMY; PRIORITY JOURNAL; SCORING SYSTEM; TUMOR VOLUME;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS;

EID: 84878646754     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12004     Document Type: Article

References (21)

1. Ljungberg B, Cowan NC, Hanbury DC etal. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 2010; 58: 398-406.
2. CARMENA. Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib, 2009 [online]. [Cited 21 Nov 2011.] Available from URL: http://clinicaltrials.gov/ct2/show/NCT00930033?term=renal+cancer&recr=Open&intr=nephrectomy&rank=2
3. EORTC. Randomized Phase III Trial Comparing Presurgical Sunitinib Followed by Nephrectomy and Sunitinib Versus Nephrectomy Followed by Sunitinib in Patients with Synchronous Metastatic Renal Cell Carcinoma, 2010 [online]. [Cited 15 Jul 2012.] Available from URL: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10561
4. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin. Cancer Res. 2007; 13: 697s-702s.
5. Motzer RJ, Agarwal N, Beard C etal. NCCN clinical practice guidelines in oncology: kidney cancer. J. Natl. Compr. Canc. Netw. 2009; 7: 618-630.
6. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982; 247: 2543-2546.
7. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996; 15: 361-387.
8. Richey SL, Culp SH, Jonasch E etal. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann. Oncol. 2011; 22: 1048-1053.
9. Crispen PL, Blute ML. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma. Curr. Urol. Rep. 2012; 13: 38-46.
10. You D, Jeong IG, Ahn JH etal. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J. Urol. 2011; 185: 54-59.
11. Powles T, Blank C, Chowdhury S etal. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol. 2011; 60: 448-454.
12. Abdollah F, Sun M, Thuret R etal. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann. Surg. Oncol. 2011; 18: 2988-2996.
13. Capitanio U, Zini L, Perrotte P etal. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology 2008; 72: 1090-1095.
14. Flanigan RC, Salmon SE, Blumenstein BA etal. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 2001; 345: 1655-1659.
15. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-970.
16. Zini L, Capitanio U, Perrotte P etal. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009; 73: 342-346.
17. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 2007; 100: 755-759.
18. Morvan JB, Veyrieres JB, Mimouni O, Cathelinaud O, Allali L, Verdalle P. Clear-cell renal carcinoma metastasis to the base of the tongue and sphenoid sinus: two very rare atypical ENT locations. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2011; 128: 91-94.
19. Han KR, Pantuck AJ, Bui MH etal. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003; 61: 314-319.
20. Culp SH, Tannir NM, Abel EJ etal. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010; 116: 3378-3388.
21. Bianchi M, Sun M, Jeldres C etal. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann. Oncol. 2012; 23: 973-980.